Quantcast

Latest Anastrozole Stories

Reducing Risk Of Breast Cancer With Promising New Drug Treatment
2013-12-12 10:25:15

Rebekah Eliason for redOrbit.com – Your Universe Online There is good news for postmenopausal women who are at high risk for developing breast cancer. According to a new study, taking the drug anastrozole for five years reduced the likelihood of developing the disease by 53 percent when compared with women who took a placebo. Approximately 80 percent of women in the United States who are diagnosed with breast cancer have tumors that contain high levels of hormone receptors. These...

2013-09-13 08:16:31

Assay accurately distinguishes patients at continued risk after five years of estrogen-blocking therapy from those who need no additional treatment A comparison of three methods of predicting the risk of recurrence in women treated for estrogen-receptor (ER)-positive breast cancer finds that only the breast cancer index (BCI) – a biomarker based on the expression levels of seven tumor-specific genes – accurately identifies patients who continue to be at risk after five years of...

2012-08-28 10:25:40

New research published in BioMed Central's open access journal BMC Medicine reassessing clinical data from trials, which investigate ways of treating side effects of therapy for prostate cancer, finds that tamoxifen, an anti-estrogen used to treat breast cancer, is also able to suppress gynecomastia and breast pain in men. Prostate cancer is one of the most common cancers in men and early treatment is usually very successful. Androgen-suppression therapy is often used to slow down...

2012-08-02 22:21:21

New treatment option extends median survival time by more than 6 months Postmenopausal women with the most common type of metastatic breast cancer now have a new treatment option that lengthens their lives, according a study led by UC Irvine oncologist Dr. Rita Mehta and conducted by the Southwest Oncology Group. The findings appear in the Aug. 2 issue of the New England Journal of Medicine. A combination of the two anti-estrogen drugs anastrozole and fulvestrant extended the median...

2012-08-02 22:18:40

Study published in New England Journal of Medicine A study co-authored by a Loyola researcher and published in the New England Journal of Medicine is offering new hope to women with advanced breast cancer. The study found that combing two drugs that normally are each given as single agents significantly extended the lives of women with metastatic breast cancer. Kathy Albain, MD, a breast cancer specialist at Loyola University Medical Center, is among the main authors of the study....

2012-03-24 03:41:35

Results from a phase III clinical trial evaluating a new treatment for breast cancer in post-menopausal women show that the combination of two cancer drugs, everolimus and exemestane, significantly improves bone strength and reduces the chances of cancer spreading (metastasising) in the bone. Professor Michael Gnant told the eighth European Breast Cancer Conference (EBCC-8) today (Friday) that the latest results from the BOLERO-2 trial would change clinical practice. "These results...

2012-03-24 03:36:40

Treatment with aromatase inhibitors enables some women to have lumpectomy Preoperative treatment with aromatase inhibitors increases the likelihood that postmenopausal women with estrogen receptor-positive breast cancer will be able to have breast-conserving surgery rather than a mastectomy, according to the results of a national clinical trial presented today at the Society of Surgical Oncology annual meeting in Orlando, Fla. "We found that half of the postmenopausal women in the study...

2012-03-07 11:00:53

Two studies published March 6 in the Journal of the National Cancer Institute provide insights about the CYP2D6 genotype in postmenopausal breast cancer patients and represent a major step forward in understanding the usefulness of CYP2D6 testing for deciding whether or not a patient should receive adjuvant tamoxifen for treatment of early-stage breast cancer. Both studies found that CYP2D6 genotypes that were indicative of reduced activity of enzymes that metabolize tamoxifen did not predict...


Word of the Day
endocarp
  • The hard inner (usually woody) layer of the pericarp of some fruits (as peaches or plums or cherries or olives) that contains the seed.
This word comes from the Greek 'endon,' in, within, plus the Greek 'karpos', fruit.
Related